Upon joining the study, an initial assessment will be conducted to confirm eligibility. This includes a review of medical history and a physical examination.

Blood tests and imaging studies may be performed to ensure there is no evidence of liver metastases and to confirm the presence of colorectal cancer.

The treatment plan will be discussed, including the medications involved and their administration methods.

Participants will receive a combination of medications: volrustomig, FOLFIRI (which includes fluorouracil, irinotecan hydrochloride trihydrate, and folinic acid), and bevacizumab. These medications are administered through an intravenous infusion, which means they are given directly into a vein.

The medications will be administered in cycles. Each cycle typically lasts two weeks, with specific days designated for receiving the infusions.

The exact dosage and schedule will be determined by the study team based on individual health status and response to treatment.

Regular monitoring will occur throughout the study to assess the safety and effectiveness of the treatment.

This includes routine blood tests, imaging studies, and physical examinations to track progress and detect any side effects.

Follow-up visits will be scheduled to evaluate the overall health and response to the treatment.

These visits will help determine the progression-free survival, which is the time during and after treatment that the cancer does not get worse.

At the end of the treatment period, a comprehensive evaluation will be conducted to assess the overall outcomes.

This will include a final review of all test results and a discussion of the next steps in care, if necessary.